493 related articles for article (PubMed ID: 19681899)
1. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
Chapple C; De Ridder D
BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
[No Abstract] [Full Text] [Related]
2. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
3. [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
[TBL] [Abstract][Full Text] [Related]
4. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Leong RK; De Wachter SG; van Kerrebroeck PE
Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
[TBL] [Abstract][Full Text] [Related]
5. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Haferkamp A
Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
8. The case for bladder botulinum toxin application.
Kim DK; Thomas CA; Smith C; Chancellor MB
Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
[TBL] [Abstract][Full Text] [Related]
9. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Cartwright R; Cardozo L
J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
[No Abstract] [Full Text] [Related]
10. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
11. Electrical and mechanical office-based neuromodulation.
Kacker R; Lay A; Das A
Urol Clin North Am; 2013 Nov; 40(4):581-9. PubMed ID: 24182977
[TBL] [Abstract][Full Text] [Related]
12. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Lemack GE
Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
[No Abstract] [Full Text] [Related]
13. [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].
Leicht W; Hampel C; Thüroff J
Urologe A; 2012 Mar; 51(3):348-51. PubMed ID: 22399111
[TBL] [Abstract][Full Text] [Related]
14. Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience.
Chartier-Kastler E
BJU Int; 2008 Feb; 101(4):417-23. PubMed ID: 18070181
[No Abstract] [Full Text] [Related]
15. Overactive bladder syndrome - management and treatment options.
Arnold J; McLeod N; Thani-Gasalam R; Rashid P
Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
[TBL] [Abstract][Full Text] [Related]
16. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
17. The current standing of intramural injection of botulinum neurotoxin in managing the overactive bladder.
Drake MJ
BJU Int; 2008 Jul; 102 Suppl 1():1. PubMed ID: 18665970
[No Abstract] [Full Text] [Related]
18. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection.
Cohen BL; Rivera R; Barboglio P; Gousse A
J Urol; 2007 Mar; 177(3):1006-10; discussion 1010. PubMed ID: 17296397
[TBL] [Abstract][Full Text] [Related]
19. [Standard pharmacological treatment and new therapies for overactive bladder].
Del Popolo G; Mencarini M; Li Marzi V
Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
[TBL] [Abstract][Full Text] [Related]
20. Changing treatments for overactive bladder.
Waine E; Stott M
Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
